MicroRNA Expression Analysis for Oocyte Competence Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting competent oocytes or embryos for IVF have limited predictive power, leading to low pregnancy and birth rates, with existing techniques relying on morphological criteria that are not highly reliable.
Innovation Solution
A method involving the measurement of specific microRNA expression levels in cumulus cells surrounding oocytes or embryos, including hsa-mir-103-1, hsa-mir-1826, let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7f, and others, to predict implantation potential and pregnancy outcome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If morphological criteria are used for embryo selection, then the selection process is simple and non-invasive, but the predictive power and reliability are limited
Solution Approach 1:
The patent uses cumulus cells as an intermediary to indirectly assess oocyte and embryo competence. Instead of directly analyzing the oocyte or embryo (which would be invasive), the method measures microRNA expression in the surrounding cumulus cells, which reflect the biological state of the oocyte-embryo complex. This intermediary approach enables reliable prediction without direct intervention.
Solution Approach 2:
The patent transitions from morphological parameters (visual characteristics) to molecular parameters (microRNA expression levels). By measuring the expression levels of specific microRNAs in cumulus cells, the method achieves higher predictive power through quantitative molecular data rather than qualitative morphological assessment.
2Reliability
If direct biomarker analysis of oocytes or embryos is performed, then predictive accuracy improves, but invasive methods are required which raise legal and ethical issues
Solution Approach 1:
The patent employs cumulus cells as a non-invasive intermediary that surrounds the oocyte and embryo. By analyzing microRNA expression in these accessible cumulus cells, the method achieves predictive accuracy comparable to direct biomarker analysis without the ethical and legal problems of directly manipulating or analyzing the oocyte or embryo itself.
3Productivity
If multiple embryos are transferred to increase pregnancy rate, then pregnancy outcome improves, but multiple gestations and associated healthcare costs increase
Solution Approach 1:
The patent extracts and identifies the specific molecular signature (microRNA expression profile) of competent embryos. By isolating this biological marker, the method enables selective transfer of only the most competent embryos, thereby achieving high pregnancy rates with fewer transferred embryos and reducing the risk of multiple gestations.
Solution Approach 2:
The method provides feedback about embryo competence through microRNA expression analysis before transfer. This feedback mechanism allows clinicians to select embryos with the highest implantation potential, optimizing the number of embryos that need to be transferred to achieve desired pregnancy outcomes while minimizing multiple gestation risks.
Data Source
AI summary
The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.